Completed PHASE4 INTERVENTIONAL 4-arm NCT01446445

Individualization of Ganciclovir and Valganciclovir Doses Using Bayesian Prediction in Renal Transplant Patients.

Individualization of Ganciclovir and Valganciclovir Doses in Renal Transplant Patients for Prophylaxis or Treatment of Cytomegalovirus(CMV)Infection Using Bayesian Prediction.

Sponsor: Ministerio de Sanidad, Servicios Sociales e Igualdad

Conditions Infection in Solid Organ Transplant Recipients

Interventions Ganciclovir/ Valganciclovir according to PK model Ganciclovir/ Valganciclovir according to SPC

Updated 5 times since 2017 Last updated: Mar 25, 2015 Started: Dec 31, 2011 Primary completion: Aug 31, 2014 Completion: Aug 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Infection in Solid Organ Transplant Recipients, this trial is completed. The trial is conducted by Ministerio de Sanidad, Servicios Sociales e Igualdad and has accumulated 5 data snapshots since 2011. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Dec 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ministerio de Sanidad, Servicios Sociales e Igualdad
Nuria Lloberas

Data source: Hospital Universitari de Bellvitge

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• L'Hospitalet de Llobregat, Spain